EIF1

Across TCGA pan-cancer cohorts, EIF1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EIF1 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EIF1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated EIF1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where EIF1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.898	0.676	<.001	31	view →
LUAD	DFS	Median	All	0.975	0.862	.001	29	view →
CCRCC	DFS	Tertile	All	0.624	0.882	.024	8	view →
LSCC	OS	Median	III,IV	0.418	0.826	.015	5	view →
UCEC	DFS	Tertile	All	0.950	0.829	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EIF1–PDAC (DFS)

Open the PDAC breakdown →